vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Axil Brands, Inc. (AXIL). Click either name above to swap in a different company.
Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $8.1M, roughly 1.3× Axil Brands, Inc.). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 8.7%, a 14.8% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 5.2%). Over the past eight quarters, Axil Brands, Inc.'s revenue compounded faster (12.1% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Axil Brands, Inc. is a U.S.-headquartered company that designs, manufactures and markets premium hearing protection products, audio enhancement devices and personal audio accessories. Its offerings include custom-fit earplugs, Bluetooth-enabled hearing buds for work, sports and leisure use, serving both consumer and professional segments across global markets.
ABUS vs AXIL — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $8.1M |
| Net Profit | $2.5M | $704.9K |
| Gross Margin | — | 68.1% |
| Operating Margin | 13.9% | 11.1% |
| Net Margin | 23.5% | 8.7% |
| Revenue YoY | 522.2% | 5.2% |
| Net Profit YoY | 112.7% | 11.2% |
| EPS (diluted) | $0.01 | $0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $8.1M | ||
| Q3 25 | — | $6.9M | ||
| Q2 25 | $10.7M | $5.8M | ||
| Q1 25 | — | $6.9M | ||
| Q4 24 | — | $7.7M | ||
| Q3 24 | — | $5.9M | ||
| Q2 24 | — | $6.5M | ||
| Q1 24 | — | $6.5M |
| Q4 25 | — | $704.9K | ||
| Q3 25 | — | $334.3K | ||
| Q2 25 | $2.5M | $-245.6K | ||
| Q1 25 | — | $576.7K | ||
| Q4 24 | — | $633.7K | ||
| Q3 24 | — | $-109.8K | ||
| Q2 24 | — | $49.5K | ||
| Q1 24 | — | $781.1K |
| Q4 25 | — | 68.1% | ||
| Q3 25 | — | 67.6% | ||
| Q2 25 | — | 70.0% | ||
| Q1 25 | — | 71.7% | ||
| Q4 24 | — | 71.1% | ||
| Q3 24 | — | 71.0% | ||
| Q2 24 | — | 71.5% | ||
| Q1 24 | — | 71.5% |
| Q4 25 | — | 11.1% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | 13.9% | 0.8% | ||
| Q1 25 | — | 8.4% | ||
| Q4 24 | — | 8.7% | ||
| Q3 24 | — | -2.4% | ||
| Q2 24 | — | 2.6% | ||
| Q1 24 | — | -1.6% |
| Q4 25 | — | 8.7% | ||
| Q3 25 | — | 4.9% | ||
| Q2 25 | 23.5% | -4.3% | ||
| Q1 25 | — | 8.3% | ||
| Q4 24 | — | 8.2% | ||
| Q3 24 | — | -1.9% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | — | 12.1% |
| Q4 25 | — | $0.09 | ||
| Q3 25 | — | $0.04 | ||
| Q2 25 | $0.01 | $-0.03 | ||
| Q1 25 | — | $0.07 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | — | $-0.02 | ||
| Q2 24 | — | $0.11 | ||
| Q1 24 | — | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $5.0M |
| Total DebtLower is stronger | $0 | $138.3K |
| Stockholders' EquityBook value | $83.0M | $11.1M |
| Total Assets | $103.3M | $16.2M |
| Debt / EquityLower = less leverage | 0.00× | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.0M | ||
| Q3 25 | — | $4.1M | ||
| Q2 25 | $37.4M | $4.8M | ||
| Q1 25 | — | $4.7M | ||
| Q4 24 | — | $5.2M | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $3.3M | ||
| Q1 24 | — | $4.9M |
| Q4 25 | — | $138.3K | ||
| Q3 25 | — | $139.2K | ||
| Q2 25 | $0 | $140.2K | ||
| Q1 25 | — | $141.0K | ||
| Q4 24 | — | $143.3K | ||
| Q3 24 | — | $144.3K | ||
| Q2 24 | — | $146.6K | ||
| Q1 24 | — | — |
| Q4 25 | — | $11.1M | ||
| Q3 25 | — | $10.2M | ||
| Q2 25 | $83.0M | $9.7M | ||
| Q1 25 | — | $9.7M | ||
| Q4 24 | — | $8.8M | ||
| Q3 24 | — | $7.9M | ||
| Q2 24 | — | $7.7M | ||
| Q1 24 | — | $8.8M |
| Q4 25 | — | $16.2M | ||
| Q3 25 | — | $15.4M | ||
| Q2 25 | $103.3M | $12.9M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $13.7M | ||
| Q3 24 | — | $11.4M | ||
| Q2 24 | — | $11.0M | ||
| Q1 24 | — | $12.7M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | 0.00× | 0.01× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $934.8K |
| Free Cash FlowOCF − Capex | — | $906.4K |
| FCF MarginFCF / Revenue | — | 11.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.3% |
| Cash ConversionOCF / Net Profit | -6.24× | 1.33× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $934.8K | ||
| Q3 25 | — | $-739.2K | ||
| Q2 25 | $-15.7M | $194.4K | ||
| Q1 25 | — | $-169.9K | ||
| Q4 24 | — | $1.0M | ||
| Q3 24 | — | $897.3K | ||
| Q2 24 | — | $-336.6K | ||
| Q1 24 | — | $-912.8K |
| Q4 25 | — | $906.4K | ||
| Q3 25 | — | $-747.6K | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-258.2K | ||
| Q4 24 | — | $941.1K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-394.9K | ||
| Q1 24 | — | $-922.1K |
| Q4 25 | — | 11.1% | ||
| Q3 25 | — | -10.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -3.7% | ||
| Q4 24 | — | 12.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -6.1% | ||
| Q1 24 | — | -14.3% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | 1.33× | ||
| Q3 25 | — | -2.21× | ||
| Q2 25 | -6.24× | — | ||
| Q1 25 | — | -0.29× | ||
| Q4 24 | — | 1.59× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -6.80× | ||
| Q1 24 | — | -1.17× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
